The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday.
根据将于周一公布的一项研究，牛津/阿斯利康(Oxford/AstraZeneca)新型冠状病毒疫苗对最早在南非发现的变异病毒引发的轻中症似乎不具保护效力。
您已阅读4%（300字），剩余96%（6644字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。